Companies › Tavotek Biotherapeutics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TAVO101 | – | Phase 2 | Atopic Dermatitis | – |
| TAVO412 | – | Phase 1 | Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06176040 | TAVO101 | Phase 2 | Atopic Dermatitis | Immunology | Mar 2025 |
| NCT06761651 | TAVO412 | Phase 1 | Cancer | Oncology | Jan 2026 |
No annotated target.
–
Xizang Haisco Pharmaceutical Telios Pharma Molecure Antengene Biologics Ganzhou Hemay Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.